Renowned higher education researcher Dr. Adrianna Kezar will be visiting campus on November 7-8 We invite staff and faculty ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

• Teen Community Service at 3:30 p.m. Oct. 21. High school students age 14-18 who need service hours can make cat and dog ...

On Thursday, Kezar Life Sciences Inc (KZR) stock saw a decline, ending the day at $0.82 which represents a decrease of $-0.07 or -7.87% from the prior close of $0.89. The stock opened at $0.86 and ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Kezar Life Sciences (KZR – Research Report).

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...